article thumbnail

Treatment options for Crohn’s disease expand after Rinvoq approval

Pharmaceutical Technology

The US Food and Drug Administration (FDA) has approved AbbVie’s Rinvoq (upadacitinib) for patients with Crohn’s disease who do not respond to TNF blockers, a common immune suppressant treatment for the condition.

article thumbnail

Eyeing emergency use of COVID-19 drug, Humanigen partners with Lonza to make it

pharmaphorum

The antibody – called lenzilumab – targets colony stimulating factor 2 (CSF2) and granulocyte-macrophage colony stimulating factor (GM-CSF), two cytokines that are linked to the runaway immune response that can result in serious lung damage in COVID-19.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Alcohol Intolerance

RX Note

Alcohol allergy is an immune system response. External Links Mayo Clinic - Alcohol Intolerance Cleveland Clinic - Alcohol Intolerance Reactions to Alcohol Histamine and Histamine Intolerance, 2007 NOTE: People often confuse alcohol intolerance and alcohol allergy, but they are not the same condition.

article thumbnail

Leading innovators in HIV peptides for the pharmaceutical industry

Pharmaceutical Technology

HIV proteins or peptides are very immunogenic, and when utilised as experimental immunogens, they can elicit strong cellular and humoral immune reactions. A piece of an HIV protein, an epitope from an HIV protein, or a mixture of several HIV proteins or fragments of them can all act as the antigenic polypeptide and produce an immune response.

article thumbnail

Innovation in immuno-oncology: Leading companies in monoclonal antibody conjugates for cancer treatment

Pharmaceutical Technology

It provides medicines for the treatment of cancer, other auto-immune diseases, central nervous system disorders, ophthalmological disorders, infectious diseases, and respiratory diseases. Hoffmann-La Roche is the leading patent filer in monoclonal antibody conjugates for cancer treatment.

article thumbnail

Innovation in immuno-oncology: Leading companies in oncolytic viral proteins

Pharmaceutical Technology

Its platform has capabilities to be used in combination with CAR-T and other cell therapies to overcome poor immune cell infiltration, immunosuppressive properties of tumour microenvironment, and systematic toxicity issues. The company has an operational presence in the US and the UK (headquartered in Abingdon, Oxfordshire, UK).

article thumbnail

Disease of the Month: IgA Nephropathy

PharmaShots

IgA immune complexes are higher in circulation when patients have respiratory infections such as a cough or sore throat, therefore, many of them end up depositing in the kidneys and this is when patients with IgA nephropathy typically present with symptoms such as hematuria (blood in the urine). Mayo Clinic 2. GlobeNewswire 5.